Correlation Between Viracta Therapeutics and Alx Oncology

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Alx Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Alx Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Alx Oncology Holdings, you can compare the effects of market volatilities on Viracta Therapeutics and Alx Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Alx Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Alx Oncology.

Diversification Opportunities for Viracta Therapeutics and Alx Oncology

0.55

Correlation Coefficient

Viracta Therapeutics  Alx Oncology

Very weak diversification

The 3 months correlation between Viracta and Alx is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Alx Oncology Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alx Oncology Holdings and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Alx Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alx Oncology Holdings has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Alx Oncology go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Alx Oncology

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Alx Oncology. But the stock apears to be less risky and, when comparing its historical volatility, Viracta Therapeutics is 1.03 times less risky than Alx Oncology. The stock trades about -0.2 of its potential returns per unit of risk. The Alx Oncology Holdings is currently generating about -0.07 of returns per unit of risk over similar time horizon. If you would invest  182.00  in Alx Oncology Holdings on August 30, 2024 and sell it today you would lose (31.00) from holding Alx Oncology Holdings or give up 17.03% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Viracta Therapeutics  vs.  Alx Oncology Holdings

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Alx Oncology Holdings

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alx Oncology Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Viracta Therapeutics and Alx Oncology

The main advantage of trading using opposite Viracta Therapeutics and Alx Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Alx Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will offset losses from the drop in Alx Oncology's long position.

The idea behind Viracta Therapeutics and Alx Oncology Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.